🇺🇸 FDA
Patent

US 8697082

Prevention and treatment of synucleinopathic and amyloidogenic disease

granted A61KA61K2039/505A61K38/1709

Quick answer

US patent 8697082 (Prevention and treatment of synucleinopathic and amyloidogenic disease) held by The Regents of the University of California expires Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Apr 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 10 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K2039/505, A61K38/1709, A61K39/0007